Clinical Trial Update: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol [Phase 2, Phase 3]

View source ↗

Summary

The DETERMINE master screening protocol is a platform trial designed to determine extended therapeutic indications for existing drugs in rare molecularly define…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Solid Tumor

Snippet

Sponsor: Cancer Research UK | Conditions: Haematological Malignancy, Solid Tumour | Phase 2, Phase 3 | Status: RECRUITING